생명공학 시장 : 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of biotechnology Market

The global biotechnology market was valued at USD 1,376.1 billion in 2025 and is projected to grow from USD 1,491.5 billion in 2026 to USD 4,334.8 billion by 2034, registering a CAGR of 14.3% during the forecast period. North America dominated the biotechnology market with a 43.34% market share in 2025, supported by strong investments in biopharmaceutical research, advanced manufacturing capabilities, and rapid technological innovation.

Biotechnology involves the use of living organisms, biological systems, and cellular processes to develop products and technologies for healthcare, agriculture, industrial manufacturing, and environmental sustainability. The industry is experiencing rapid expansion due to breakthroughs in genomics, gene editing, synthetic biology, bioinformatics, and cell-based therapies. Increasing demand for biologics, personalized medicine, and advanced diagnostics is accelerating market growth globally.

A major factor driving the biotechnology market is the increasing investment in research and development. Biotechnology companies consistently allocate a significant portion of their revenues to innovation, while governments worldwide continue to support biotechnology through grants, funding initiatives, and strategic policies. These investments are helping accelerate commercialization of advanced therapies, including cell and gene therapies, RNA-based medicines, and regenerative medicine solutions.

For instance, in 2025, biotechnology R&D represented approximately 17% of the USD 782 billion invested by the U.S. business sector in research and development activities. Additionally, AI-powered drug discovery platforms are significantly reducing development timelines, improving research efficiency, and lowering costs across biotechnology applications.

Biotechnology Market Trends

Expansion of Single-Use and Flexible Manufacturing

One of the most significant trends in the biotechnology market is the growing adoption of single-use and flexible manufacturing systems. These technologies reduce contamination risks, lower operational costs, shorten production cycles, and improve scalability. According to industry surveys, single-use systems were utilized in approximately 87% of biopharmaceutical manufacturing facilities in 2024.

In March 2025, Cytiva expanded its Xcellerex X-platform with new 500L and 2,000L single-use bioreactors, supporting advanced therapeutic manufacturing and enhancing production flexibility.

Market Drivers

Rising Demand for Biopharmaceutical Drugs

Biopharmaceutical products continue to gain preference over conventional small-molecule drugs due to their superior efficacy, targeted action, and improved safety profiles. Increasing demand for monoclonal antibodies, recombinant proteins, vaccines, and advanced biologics is significantly driving biotechnology market growth.

Several blockbuster drugs, including Keytruda, Mounjaro, Dupixent, Skyrizi, Darzalex, and Opdivo, generated substantial revenue in 2025, highlighting the growing importance of biotechnology-based therapeutics.

Market Restraints

High Research and Development Costs

Despite strong growth prospects, biotechnology companies face significant challenges related to high R&D expenses. Developing biologics, cell therapies, and gene therapies requires substantial investments, often ranging from USD 2 billion to USD 4 billion, along with lengthy development timelines of 10-12 years.

High failure rates during clinical trials further increase financial risks and can delay commercialization.

Market Opportunities

Sustainable and Low-Carbon Production Technologies

The shift toward sustainable manufacturing is creating significant opportunities for biotechnology companies. Industrial biotechnology enables the production of bio-based chemicals, renewable fuels, enzymes, and environmentally friendly materials that reduce carbon emissions and resource consumption.

Growing adoption of precision fermentation and renewable feedstocks across industries is expected to create substantial growth opportunities throughout the forecast period.

Market Challenges

Regulatory Complexity Across Regions

Biotechnology companies face challenges associated with diverse regulatory requirements across global markets. Differences in clinical trial standards, manufacturing validation requirements, and long-term safety monitoring often increase costs and delay product approvals.

The complexity becomes even greater for emerging technologies such as gene therapy, mRNA platforms, and advanced biologics, which require extensive regulatory scrutiny.

Segment Analysis

By Technology

The bioprocessing technologies segment dominated the market in 2025 due to increasing biologics production, expansion of manufacturing facilities, and strong investments by industry participants.

The genomics & genetic analysis technologies segment is expected to witness substantial growth during the forecast period, driven by advancements in precision medicine and genetic testing.

By Application

The biopharmaceutical discovery & preclinical research segment held the largest market share in 2025 due to increasing R&D expenditures and growing focus on innovative therapeutic development.

The cell & gene therapy segment is anticipated to register the fastest growth through 2034, supported by expanding clinical pipelines and regulatory approvals.

By End User

Pharmaceutical & biotechnology companies dominated the biotechnology market in 2025 and are expected to account for 53.8% of the market in 2026. Rising investments in manufacturing expansion, product development, and advanced therapeutic research continue to support segment growth.

Regional Analysis

North America

North America led the biotechnology market with a valuation of USD 596.5 billion in 2025. Strong biopharmaceutical research infrastructure, advanced manufacturing capabilities, and high healthcare spending contribute to regional dominance.

The U.S. biotechnology market is projected to reach USD 615.5 billion in 2026, accounting for approximately 41.3% of global revenue.

Europe

Europe is expected to reach USD 386.6 billion in 2026, driven by growing biosimilar adoption, public funding support, and expansion of biologics manufacturing capacity.

Germany is projected to reach USD 79.1 billion, while the U.K. market is expected to achieve USD 86.4 billion in 2026.

Asia Pacific

Asia Pacific is projected to reach USD 293.9 billion in 2026, supported by growing clinical trial activity, increasing R&D investments, and expanding GMP manufacturing capacity.

China is expected to generate USD 88.3 billion, India USD 52.3 billion, and Japan USD 54.0 billion in 2026.

Latin America and Middle East & Africa

Latin America is projected to reach USD 86.2 billion in 2026, while the GCC biotechnology market is expected to attain USD 32.2 billion. Improved healthcare infrastructure and increasing access to advanced therapies are supporting regional growth.

Competitive Landscape

The biotechnology market is highly competitive, with leading companies focusing on pipeline expansion, strategic collaborations, acquisitions, and innovative product launches.

Major companies operating in the market include:

• Eli Lilly and Company
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AstraZeneca
• Amgen Inc.
• Gilead Sciences, Inc.
• Vertex Pharmaceuticals Incorporated
• Moderna, Inc.
• BioNTech SE
• Alnylam Pharmaceuticals, Inc.
• argenx
• Genmab A/S
• Insmed Incorporated
• CELLTRION INC.

Recent industry developments include Sartorius AG's expansion of sustainable bioprocessing solutions in January 2026, Thermo Fisher Scientific's expansion of bioprocess design centers across Asia in December 2025, and Merck KGaA's new filtration manufacturing facility in Ireland announced in September 2025.

Conclusion

The biotechnology market is entering a period of rapid expansion driven by breakthroughs in genomics, biologics, cell and gene therapy, synthetic biology, and AI-powered drug discovery. The market is expected to increase from USD 1,376.1 billion in 2025 to USD 4,334.8 billion by 2034, reflecting strong long-term growth potential. Rising R&D investments, increasing demand for advanced therapeutics, adoption of sustainable manufacturing technologies, and expanding healthcare applications will continue to shape the future of the biotechnology industry. While regulatory complexities and high development costs remain challenges, continuous innovation and strategic investments are expected to drive substantial opportunities across global markets through 2034.

Segmentation By Technology, Application, End-User, and Region

By Technology * Genomics & Genetic Analysis Technologies

• Synthetic Biology & Genetic Engineering Technologies
• Gene Editing Technologies
• Cell Engineering & Cell Culture Technologies
• Bioprocessing Technologies
• Nanobiotechnology
• Others

By Application * Biopharmaceutical Discovery & Preclinical Research

• Cell & Gene Therapy
• Molecular Diagnostics
• Industrial Biotechnology
• RNA Therapeutics & Nucleic Acid Medicines
• Precision Medicine & Biomarker Development
• Regenerative Medicine & Tissue Engineering
• Others

By End-User * Pharmaceutical & Biotechnology Companies

• CROs & CDMOs
• Academic & Research Institutes
• Others

By Region * North America (By Technology, Application, End-User, and Country)

• U.S.
• Canada
• Europe (By Technology, Application, End-User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, Application, End-User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, Application, End-User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, Application, End-User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Biotechnology
• 4.2. Prevalence of Key Diseases, By Key Regions, 2025
• 4.3. Regulatory Scenario, By Key Countries/Regions
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.6. Overview: Investment Trends in Biotechnology Market

5. Global Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Genomics & Genetic Analysis Technologies
  • 5.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 5.1.3. Gene Editing Technologies
  • 5.1.4. Cell Engineering & Cell Culture Technologies
  • 5.1.5. Bioprocessing Technologies
  • 5.1.6. Nanobiotechnology
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 5.2.2. Cell & Gene Therapy
  • 5.2.3. Molecular Diagnostics
  • 5.2.4. Industrial Biotechnology
  • 5.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 5.2.6. Precision Medicine & Biomarker Development
  • 5.2.7. Regenerative Medicine & Tissue Engineering
  • 5.2.8. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Pharmaceutical and Biotechnology Companies
  • 5.3.2. CROs & CDMOs
  • 5.3.3. Academic & Research Institutions
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Genomics & Genetic Analysis Technologies
  • 6.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 6.1.3. Gene Editing Technologies
  • 6.1.4. Cell Engineering & Cell Culture Technologies
  • 6.1.5. Bioprocessing Technologies
  • 6.1.6. Nanobiotechnology
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 6.2.2. Cell & Gene Therapy
  • 6.2.3. Molecular Diagnostics
  • 6.2.4. Industrial Biotechnology
  • 6.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 6.2.6. Precision Medicine & Biomarker Development
  • 6.2.7. Regenerative Medicine & Tissue Engineering
  • 6.2.8. Other
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Pharmaceutical and Biotechnology Companies
  • 6.3.2. CROs & CDMOs
  • 6.3.3. Academic & Research Institutions
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Genomics & Genetic Analysis Technologies
  • 7.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 7.1.3. Gene Editing Technologies
  • 7.1.4. Cell Engineering & Cell Culture Technologies
  • 7.1.5. Bioprocessing Technologies
  • 7.1.6. Nanobiotechnology
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 7.2.2. Cell & Gene Therapy
  • 7.2.3. Molecular Diagnostics
  • 7.2.4. Industrial Biotechnology
  • 7.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 7.2.6. Precision Medicine & Biomarker Development
  • 7.2.7. Regenerative Medicine & Tissue Engineering
  • 7.2.8. Other
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Pharmaceutical and Biotechnology Companies
  • 7.3.2. CROs & CDMOs
  • 7.3.3. Academic & Research Institutions
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Genomics & Genetic Analysis Technologies
  • 8.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 8.1.3. Gene Editing Technologies
  • 8.1.4. Cell Engineering & Cell Culture Technologies
  • 8.1.5. Bioprocessing Technologies
  • 8.1.6. Nanobiotechnology
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 8.2.2. Cell & Gene Therapy
  • 8.2.3. Molecular Diagnostics
  • 8.2.4. Industrial Biotechnology
  • 8.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 8.2.6. Precision Medicine & Biomarker Development
  • 8.2.7. Regenerative Medicine & Tissue Engineering
  • 8.2.8. Other
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Pharmaceutical and Biotechnology Companies
  • 8.3.2. CROs & CDMOs
  • 8.3.3. Academic & Research Institutions
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Southeast Asia
  • 8.4.5. Australia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Genomics & Genetic Analysis Technologies
  • 9.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 9.1.3. Gene Editing Technologies
  • 9.1.4. Cell Engineering & Cell Culture Technologies
  • 9.1.5. Bioprocessing Technologies
  • 9.1.6. Nanobiotechnology
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 9.2.2. Cell & Gene Therapy
  • 9.2.3. Molecular Diagnostics
  • 9.2.4. Industrial Biotechnology
  • 9.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 9.2.6. Precision Medicine & Biomarker Development
  • 9.2.7. Regenerative Medicine & Tissue Engineering
  • 9.2.8. Other
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Pharmaceutical and Biotechnology Companies
  • 9.3.2. CROs & CDMOs
  • 9.3.3. Academic & Research Institutions
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Biotechnology Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Genomics & Genetic Analysis Technologies
  • 10.1.2. Synthetic Biology & Genetic Engineering Technologies
  • 10.1.3. Gene Editing Technologies
  • 10.1.4. Cell Engineering & Cell Culture Technologies
  • 10.1.5. Bioprocessing Technologies
  • 10.1.6. Nanobiotechnology
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Biopharmaceutical Discovery & Preclinical Research
  • 10.2.2. Cell & Gene Therapy
  • 10.2.3. Molecular Diagnostics
  • 10.2.4. Industrial Biotechnology
  • 10.2.5. RNA Therapeutics & Nucleic Acid Medicines
  • 10.2.6. Precision Medicine & Biomarker Development
  • 10.2.7. Regenerative Medicine & Tissue Engineering
  • 10.2.8. Other
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Pharmaceutical and Biotechnology Companies
  • 10.3.2. CROs & CDMOs
  • 10.3.3. Academic & Research Institutions
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Eli Lilly and Company
  • 11.2.2. AbbVie Inc.
  • 11.2.3. F. Hoffmann-La Roche Ltd
  • 11.2.4. Pfizer Inc.
  • 11.2.5. AstraZeneca
  • 11.2.6. Amgen Inc.
  • 11.2.7. Gilead Sciences, Inc.
  • 11.2.8. Vertex Pharmaceuticals Incorporated
  • 11.2.9. Moderna, Inc.
  • 11.2.10. BioNTech SE
  • 11.2.11. Alnylam Pharmaceuticals, Inc.
  • 11.2.12. argenx
  • 11.2.13. Genmab A/S
  • 11.2.14. Insmed Incorporated
  • 11.2.15. CELLTRION INC.